Brepocitinib’s Unprecedented Phase 2 Results in Neglected and Rare Cutaneous Disease

"In all honesty, I thought there was an error in the data when I first saw it because of how good it was,” Misha Rosenbach, MD, told Dermatology Times. “You're seeing dramatic response with good safety profile and no placebo response...it's hard to have cleaner or better data than that.”

In a continuing conversation, Rosenbach, professor of dermatology and rheumatology at the Hospital of the University of Pennsylvania, discussed the recent phase 2 BEACON study evaluating brepocitinib, a dual JAK1/TYK2 inhibitor, for cutaneous sarcoidosis (CS), highlighting both safety and efficacy findings and their broader implications for the field.

Although BEACON enrolled approximately 30 patients, a modest sample by common dermatologic trial standards, Rosenbach noted that this represents one of the largest prospective interventional studies conducted in CS, a rare and historically underfunded disease with no FDA-approved therapies. From a safety perspective, the results were encouraging. Baseline characteristics were generally balanced across placebo and active-treatment groups. Adverse event rates were low and comparable between placebo and brepocitinib (15 mg and 45 mg doses), with no concerning safety signals emerging. Given the comorbid complexity often seen in sarcoidosis, demonstration of a favorable safety profile was a critical first step.

Efficacy outcomes were particularly striking, according to Rosenbach. Using the validated Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI)—a reliable clinical scoring tool in which a 5-point reduction is considered clinically meaningful—both treatment arms achieved mean reductions exceeding 20 points. Notably, patients receiving 45 mg experienced especially robust responses: all achieved greater than 10-point reductions, and approximately two-thirds reached CSAMI scores below 5, suggestive of minimal residual disease. In contrast, placebo responses were minimal, producing a clear statistical and clinical separation between active treatment and control.

Rosenbach emphasized that the magnitude of improvement, combined with the absence of a meaningful placebo response, represents unusually “clean” data in a dermatologic trial. Beyond efficacy, the study demonstrates that CS can be successfully studied using validated outcome instruments and that patients, including populations historically underrepresented in trials, can be effectively enrolled.

For the dermatology community, BEACON represents proof of concept that targeted therapy can meaningfully alter disease activity in CS. For patients, it signals long-awaited therapeutic momentum in a condition historically managed with off-label immunosuppressants or systemic corticosteroids. Ongoing and future phase 3 studies will further clarify long-term safety, durability of response, and optimal dosing, but even at this stage, brepocitinib represents a promising step forward in addressing a significant unmet need.

“I'm just happy that we have something on the horizon that might offer hope for patients who are really devastated by a neglected disease that now has some promise,” Rosenbach concluded.